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In 2004, the FDA approved sorafenib, a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, for advanced renal cell carcinoma (RCC) based on 5.5 months improvement in progression free survival (PFS) compared to those treated with placebo. Soon after, sunitinib was also approved for advanced RCC based on eliciting an improve ment in PFS 1 . This success heralded a revo lution in the treatment of RCC, and coupled with the strong biological rationale of VEGF pathway dysregulation associated with the von Hippel-Lindau tumour suppressor mutation in the clear cell RCC subtype, adjuvant stud ies were vigorously pursued. In the ASSURE trial 2 , 1,943 patients with completely resected RCC were stratified by the UCLA inter national staging system and assigned 1:1:1 to sorafenib, sunitinib, or placebo for 54 weeks. The study was reported early on the advice of the Data, Safety, and Monitoring Committee, when the interim evaluation revealed low con ditional power for the primary end point to be met 2 . No significant difference in disease free survival (DFS) for either sorafenib (median 6.1 years, HR 0.97, 97.5% CI 0.80-1.17) or sunitinib (median 5.8 years, HR 1.02, 97.5% CI 0.85-1.23) was observed when compared to placebo (median 6.6 years). In addition to the important but disappointing message to the RCC community that adjuvant Second, targeting the VEGF pathway in the adjuvant setting for micrometastatic disease is a treacherous enterprise, owing to the target molecule being located on the endo thelium, and longstanding literature that started with Judah Folkman supporting the angiogenic switch being critical to transitions from cel lular dormancy to angiogenic growth 3 . One might reasonably assume that clear cell RCC falls outside this model, having inherently been angiogenically "switched on", but VEGF targeted therapy has failed to achieve expecta tions in other tumour types in previous trials. Adjuvant studies in the setting of colon can cer that used chemotherapy plus bevacizumab -a recombinant humanized monoclonal antibody against VEGFA -were also dis appointing. In the National Surgical Adjuvant Breast and Bowel Project C08 phase III trial, which included 2,672 patients with stage II or III disease, bevacizumab was administered with FOLFOX (a chemotherapy regimen for treatment of colorectal cancer, composed of folinic acid, fluorouracil, and oxaliplatin) for 6 months followed by 6 months of mono therapy, compared to 6 months of FOLFOX alone 4 . Like the ASSURE trial, no difference in DFS or overall survival was observed and the treatment came at the cost of high toxicity 4 . Adjuvant chemotherapy plus bevacizumab also failed to demonstrate a benefit in invasive DFS in triple negative breast cancer 5 , and in overall survival for both nonsmallcell lung cancer 6 and melanoma 7 . Randomized trials testing other VEGF receptor inhibitors, such as pazopanib and axitinib as adjuvant therapy in RCC are ongoing. To date, anti angiogenic therapies, despite being effective for met astatic disease, have yielded no successes in the adjuvant setting. One of the theories behind their failure is that anti angiogenesis is a cytostatic rather than cytotoxic process and thereby enables micrometastatic adaptation and ultimately, evasion. In some sense this finding lends further support to Folkman's model, which might predict in the adjuvant setting that antiangiogenic therapy is unlikely to eradicate micrometastases, as these cells reside in a state that might not require the support of tumour angiogenesis (FIG. 1) .
Finally, the enrolment for the ASSURE study included patients with stage T1b dis ease (tumour size >4 cm but <7 cm, and con fined to the kidney), grade 3 or 4 histology, therapy for risk reduction remains confined to clinical trials, this study revealed valua ble information regarding three aspects of adjuvant therapy that might directly impact patient care: agentspecific toxicities and acceptable toxicity burden in the adjuvant setting, insights into the biological processes that govern micrometastasis, and the need for accurate risk assessment.
First, it is important to note that the adverse effects of antiangiogenic agents are not triv ial. In this first, randomized comparison of sunitinib and sorafenib, the expected differ ences in toxicity profile between the two agents were observed -notably a high prevalence of rash and hand-foot syndrome with sorafenib, and fatigue with sunitinib. Strikingly, this study revealed a difference in the toxicities that will be tolerated when a patient is combating metastatic disease, where these adverse effects are considered quite manageable, compared with a setting in which the treatment intent is risk reduction, where these adverse effects led to discontinuation. The result was a midstudy dose adjustment in which the starting doses of both drugs were lowered and the overall number of patients was expanded to account for a very high level of discontinuation in both treatment arms. These observations are vital to consider when designing future adjuvant therapy studies in RCC.
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The first, highly anticipated randomized trial of adjuvant antiangiogenic therapy in renal cancer was recently reported. Although far from assuring, data from the adjuvant sorafenib or sunitinib for unfavorable renal carcinoma (ASSURE) trial offer a wealth of insights into the disease, treatments, and biological considerations for studies aimed at risk reduction.
or higher, and all histological types of RCC. The stratification on clinical risk features, and other parameters, failed to reveal any specific quality that identified patients who might benefit from the intervention, or who might be best served by avoiding the treat ment. What seem to be clearly needed are more substantive and meaningful strategies for biological classification of tumours; ide ally, this would involve identifying robust predictive markers. To date, the search for a predictive feature indicative of a response to antiangiogenic therapy has been elusive in the metastatic disease setting in which these drugs are commonly used. However, using biological signatures to stratify patients into clear risk groups can also enable adjuvant therapies to be applied more strategically. For example, in estrogenreceptorpositive breast cancer, the 21gene assay based on the OncotypeDx® (Genomic Health, USA) rapid PCR is used to predict recurrence risk and select which patients should receive adju vant endocrine or chemotherapy regardless of lymph node positivity 8 . In RCC, several expression tools have been integrated with clinical features and demonstrated to assign risk more accurately than clinical algorithms alone. Our group demonstrated a 34gene subtype predictor (known as ClearCode34), to classify patients with clear cell RCC into low risk or high risk for disease recurrence 9 . Several other expressionbased scoring algo rithms that accurately predict risk of recur rence in RCC have also been developed 10 . Tissue collection was a central feature of the ASSURE study, and one or more of the established risk assessment classifying tools should be used to determine if a subgroup can be defined that benefited from the intervention.
In summary, negative trials such as ASSURE are equally important as positive trials, and provide us with valuable lessons to take forward into future studies. Data currently do not support a role for anti angiogenic therapy as adjuvant therapy for unfavourable kidney cancer, and in a major ity of cases this treatment strategy leads to unwanted toxicity. The micrometastatic niche in RCC and the role that angio genesis has in promoting metastasis formation is peculiar and cannot be extrapolated from the macrometastatic environment. This segment of the pathophysiology of RCC requires careful exploration. Recurrence score models based on molecular char acteristics combined with clinicopatho logic markers might better refine high risk individuals with RCC. Nature Reviews | Nephrology The factors that support micrometastatic disease and early disease progression in RCC might be independent of the angiogenesis that high-tumour-burden metastatic disease requires for support. Sorafenib and sunitinib have antiangiogenic effects but might not prevent micrometastasis. VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor.
